Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series

Infection

Volumn 45, Issue 2, 2017, Pages 209-213

  Murri, Rita ^a   Fiori, Barbara ^a   Spanu, Teresa ^a   Mastrorosa, Ilaria ^a   Giovannenze, Francesca ^a   Taccari, Francesco ^a   Palazzolo, Claudia ^a   Scoppettuolo, Giancarlo ^a   Ventura, Giulio ^a   Sanguinetti, Maurizio ^a   Cauda, Roberto ^a   Fantoni, Massimo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Carbapenemase; Co trimoxazole; KPC; Multidrug resistant infections; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; AGED; ARTICLE; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; DECUBITUS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MALE; PERITONEAL FLUID; RETROSPECTIVE STUDY; SKIN ABSCESS; URINARY TRACT INFECTION; ADVERSE DRUG REACTION; ENZYMOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MIDDLE AGED; SECRETION (PROCESS); TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85011850212     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0968-x     Document Type: Article

References (26)

1. European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/table_reports.aspx. Accessed Nov 2016.
2. Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58:213–9.
3. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50:364–73.
4. Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010;15.
5. Freire MP, Abdala E, Moura ML, et al. Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients. Infection. 2015;43:315–23.
6. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–43.
7. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–8.
8. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.
9. van der Donk CF, Beisser PS, Hoogkamp-Korstanje JA, Bruggeman CA, Stobberingh EE, Antibiotic Resistance Surveillance Group. A 12 year (1998-2009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals. J Antimicrob Chemother. 2011;66:855–8.
10. Lombardi F, Gaia P, Valaperta R, et al. Emergence of Carbapenem-Resistant Klebsiella pneumoniae: progressive spread and four-year period of observation in a cardiac surgery division. Biomed Res Int. 2015;2015:871947.
11. Oteo J, Ortega A, Bartolomé R, et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother. 2015;59:3406–12.
12. Bremmer DN, Clancy CJ, Press EG, et al. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6′)-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother. 2014;58:7597–600.
13. Walsh TR, Toleman MA, Poirel L, et al. Metallo-b-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306–25.
14. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34:1–14.
15. Giani T, Pini B, Arena F, et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill 2013;18:20849.
16. ECDC. Annual epidemiological report 2013: reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: European Centre for Disease Prevention and Control; 2013. http://ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf. Accessed Jan 2017.
17. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis. 2009;48:1729–31.
18. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;23:19.
19. Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117–23.
20. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69:357–62.
21. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68:140–51.
22. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439–48.
23. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.
24. Ji S, Lv F, Du X, et al. Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing Klebsiella pneumoniae infection. Int J Infect Dis. 2015;38:108–14.
25. Limbago BM, Rasheed JK, Anderson KF, et al. IMP-producing carbapenem-resistant Klebsiella pneumoniae in the US. J Clin Microbiol. 2011;49:4239–45.
26. Ahn C, Syed A, Hu F, O’Hara JA, Rivera JI, Doi Y. Microbiological features of KPC-producing enterobacter isolates identified in a US hospital system. Diagn Microbiol Infect Dis. 2014;80:154–8.